Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo
NCT ID: NCT03273504
Last Updated: 2018-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2017-07-14
2017-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement
NCT02275832
Minoxidil 2% for Eyebrow Enhancement
NCT01672307
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
NCT05954039
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002
NCT06095739
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
NCT02549352
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)
Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.
The placebo product will be applied in the same way, on the controlateral leg.
Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)
The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
Placebo
The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)
The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
Placebo
The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* female sex
* with hypertrichosis
* agreeing not to perform epilation or scrub/peeling treatment on the test area (legs) during the week preceding the inclusion
* good general state of health
Exclusion Criteria
* lactation
* subjects whose insufficient adhesion to the study protocol is foreseeable
* sensitive skin
* oral contraceptive therapy started less than 1 year
* presence of varicose or capillary veins of surface
* hormonal therapies able to influence hair growth.
* presence of cutaneous disease on the tested area, as lesions, scars, malformations.
* diabetes
* endocrine disease
* hepatic disorder
* renal disorder
* cardiac disorder
* cancer.
* farmacological topical treatment and surgery and/or medical treatment on the treated side performed in the last 3 months
* systemic corticosteroids
* aspirin or non-steroid anti-inflammatory drugs (FANS)
* diuretic.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Derming SRL
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adele Sparavigna
Dermatologist, Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DERMING
Milan, MI, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E1517
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.